Shanghai Pharma's amisulpride tablets join national medical insurance catalog

Shanghai Pharmaceuticals Holding Co., Ltd. announced that its subsidiary, Shanghai No. 1 Pharmaceutical Co., Ltd., has successfully negotiated the inclusion of its amisulpride orally disintegrating tablets into the National Medical Insurance Catalog (2025 edition). This inclusion, effective from January 1, 2026, until December 31, 2027, is expected to enhance the drug's market share and competitive position.

The amisulpride orally disintegrating tablets, a modified formulation of a drug first launched in France in 1986 by Sanofi for adult schizophrenia, received market approval from the National Medical Products Administration in October 2025, with Shanghai No. 1 Pharmaceutical as the marketing authorization holder. As of the announcement date, there are no other companies marketing amisulpride orally disintegrating tablets in mainland China.

According to IQVIA data, the hospital procurement amount for oral amisulpride formulations reached RMB 16,841万元 in 2024. The company cautioned that sales might not meet expectations due to uncertainties in national policies and market conditions.